Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phospholamban (PLN) is a 52-amino acid integral membrane micropeptide that regulates cardiac muscle contractility and calcium homeostasis by modulating the activity of the sarco(endo)plasmic reticulum Ca2+ ATPase pump (SERCA2). In its unphosphorylated state, PLN inhibits SERCA2, reducing calcium uptake into the sarcoplasmic reticulum. Phosphorylation of PLN at Ser16 or Thr17 relieves this inhibition, increasing calcium uptake and enhancing cardiac muscle relaxation and contraction strength. Mutations in PLN are associated with dilated cardiomyopathy.
Phosphorylation-dependent regulation of SERCA2 activity. Unphosphorylated PLN inhibits SERCA2, while phosphorylated PLN relieves this inhibition, leading to increased Ca2+ uptake into the sarcoplasmic reticulum.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phospholamban (PLN/PLB).